WuXi XDC Cayman: Record revenue and backlog growth, with robust outlook and expanding global capacityQuartr·1 day ago, 10:47 AM02268-3.62%01875-0.74%
From Energy Shifts to Crypto ETFs: Assessing Hong Kong's Niche MarketsGlobal Report·1 day ago, 05:11 AM01088-0.44%01783+0.94%
TOT Biopharm FY26 H1 net loss swings to RMB 59 million; revenue drops 49.7% to RMB 246 millionPUBT·Aug 21 at 06:47 AM01875-0.74%
The Hong Kong Market's "Leftover" Bin: Who's Faking It and Who's Real?Global Report·Aug 19 at 04:44 AM01951+3.99%01875-0.74%
Margin Defense Overrides Expansion as Hong Kong Consumer and Property Sectors AdjustGlobal Report·Aug 6 at 04:14 AM02314+0.77%01179+1.59%
Nomura Cuts WUXI XDC TP to HKD82.6 on Adverse FX Impact on EarningsAASTOCKS News·Jul 26 at 10:47 PM01875-0.74%02268-3.62%
Liquidity spillovers trigger a structural repricing in Hong Kong's unclassified cornersGlobal Report·Jul 25 at 04:14 AM09600-2.03%013410.00%
BOCOM International Cuts WUXI XDC TP to HKD80; Earnings Still Expected to Deliver Strong Growth Amid FX VolatilityAASTOCKS News·Jul 15 at 01:40 AM01875-0.74%02268-3.62%
BioDlink Sets August Board Meeting to Approve Interim 2026 ResultsTip Ranks·Jul 10 at 04:40 AM01875-0.74%
WuXi XDC Unit BioDlink Signs RMB19 Million Monoclonal Antibody Manufacturing Deal With WuXi BiologicsTip Ranks·Jun 16 at 06:00 PM02268-3.62%02269-2.78%
BioDlink Shareholders Approve CDMO Master Agreement With WuXi XDCTip Ranks·Jun 11 at 07:10 AM01875-0.74%
